|By PR Newswire||
|March 6, 2014 11:31 AM EST||
NEW YORK, March 6, 2014 /PRNewswire/ -- As Risperdal gynecomastia lawsuits (http://www.risperdallawsuitcenter.com/) continue to be filed on behalf of individuals who suffered gynecomastia (male breast growth) and other complications due to their use of the atypical antipsychotic medication, Bernstein Liebhard LLP notes the publication of a new study examining the side effects associated with psychotropic medications like Risperdal. The research, which was presented this month at the 22nd European Congress of Psychiatry, suggested that early weight gain in patients being treated with such medications could be a clinically relevant marker for long-term weight gain. Among other things, the 1 year retrospective study found that weight gain of 5% or more at 1 month predicted further weight gain at 3 and 12 months.
"Numerous Risperdal lawsuits have been filed in courts around the country which claim the medication caused patients to experience weight gain, diabetes, gynecomastia and other serious side effects," says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to young men and boys who allegedly developed Risperdal gynecomastia due to their use of the antipsychotic medication.
Risperdal Gynecomastia Lawsuits
Court records indicate that hundreds of Risperdal lawsuits have been filed in a Mass Tort litigation underway in Pennsylvania's Philadelphia Court of Common Pleas on behalf of victims of male breast growth and other complications allegedly associated with the Risperdal. Among other things, plaintiffs allege that Risperdal was improperly marketed for off-label indications, including pediatric uses. They further allege that Johnson & Johnson and its Janssen Pharmaceuticals unit concealed the drug's risks, including the potential for Risperdal male breast growth. (Risperdal Litigation, case number 100300296)
This past November, Johnson & Johnson and Janssen agreed to pay $2.2 billion to settle charges with the federal government involving the marketing of Risperdal and other medications. Like plaintiffs in Risperdal male breast growth claims, the U.S. Department of Justice had charged the companies with improperly marketing the antipsychotic drug for use in children, and concealing the link between Risperdal and gynecomastia. According to the Justice Department, the settlement ranks as one of the largest ever involving health care fraud.
Alleged victims of Risperdal male breast growth could be entitled to compensation for medical expenses, lost wages, emotional distress, pain and suffering, and other injury-related damages. Find out more about filing a Risperdal lawsuit by visiting Bernstein Liebhard LLP's website. To arrange for a free case review, please contact the Firm directly by calling (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
SOURCE Bernstein Liebhard LLP